Abstract
dc:description.abstractCancer regulation is a multi-layered process driven not only by mutations in protein-coding sequences, but also by epigenetic modifications, chromatin accessibility, and sequence variations in regulatory regions that rewire gene expression programs. While promoter mutations have traditionally been studied for their effects on transcriptional output, their impact on post-transcriptional regulation remains poorly understood. In this dissertation, I investigate how sequence variations in promoter regions influence transcription, alternative splicing, and downstream cellular phenotypes in cancer. Focusing on cancer-associated promoter point mutations, I demonstrate that single-nucleotide changes within promoter regions can significantly alter alternative splicing outcomes in conjunction with changes in gene expression. Using bichromatic reporter assays, I functionally characterize promoter mutations in cancer-relevant genes and uncover a coupling between promoter sequence variation and splicing regulation. I further show that these splicing defects can be therapeutically modulated using antisense oligonucleotides and CRISPR-based strategies, highlighting regulatory sequence variation as a tractable therapeutic target. To place these findings in a broader regulatory context, I integrate large-scale protein-DNA interaction networks that map transcription factor binding, cooperativity, and antagonism across cancer promoters, demonstrating how transcription factors interpret regulatory sequence to shape gene expression programs. I extend this framework to show how transcription factors regulate gene expression with multiple layers of specificity and how transcription factor fusion proteins rewire DNA-binding landscapes in cancer. Collectively, this work establishes regulatory sequence variation as a multi-layer driver of transcriptional and post-transcriptional dysregulation in cancer, identifies promoter mutations as functional modulators of alternative splicing, and highlights both CRISPR-based and RNA-targeted therapeutic strategies capable of correcting aberrant gene regulation. These findings broaden the functional interpretation of non-coding cancer mutations and provide new insights for precision cancer therapeutics.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Biology
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Lu, Yunwei
- Advisors dc:contributor.advisor
-
- Fiszbein, Ana
- Fuxman Bass, Juan
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53586